Analysis of the proximal promoter of the human colon-specific B4GALNT2 (Sd


Journal

Biochimica et biophysica acta. Gene regulatory mechanisms
ISSN: 1876-4320
Titre abrégé: Biochim Biophys Acta Gene Regul Mech
Pays: Netherlands
ID NLM: 101731723

Informations de publication

Date de publication:
Historique:
received: 16 06 2021
revised: 26 07 2021
accepted: 09 08 2021
pubmed: 10 9 2021
medline: 31 12 2021
entrez: 9 9 2021
Statut: ppublish

Résumé

The Sd To clarify the molecular basis of Sd A short cis-regulatory region restricted to the -72 to +12 area upstream of the B4GALNT2 short-type transcript variant contained the essential promoter activity that drives the expression of the human B4GALNT2 regardless of the cell type. We further showed that B4GALNT2 transcriptional activation mostly requires ETS1 and to a lesser extent SP1. Results presented herein are expected to provide clues to better understand B4GALNT2 regulatory mechanisms.

Sections du résumé

BACKGROUND
The Sd
METHODS
To clarify the molecular basis of Sd
RESULTS
A short cis-regulatory region restricted to the -72 to +12 area upstream of the B4GALNT2 short-type transcript variant contained the essential promoter activity that drives the expression of the human B4GALNT2 regardless of the cell type. We further showed that B4GALNT2 transcriptional activation mostly requires ETS1 and to a lesser extent SP1.
CONCLUSIONS
Results presented herein are expected to provide clues to better understand B4GALNT2 regulatory mechanisms.

Identifiants

pubmed: 34500083
pii: S1874-9399(21)00065-1
doi: 10.1016/j.bbagrm.2021.194747
pii:
doi:

Substances chimiques

ETS1 protein, human 0
Oligosaccharides 0
Proto-Oncogene Protein c-ets-1 0
Sd(a) determinant 0
Sp1 Transcription Factor 0
SP1 protein, human 0
N-Acetylgalactosaminyltransferases EC 2.4.1.-
beta-1,4-N-acetyl-galactosaminyl transferase 2 EC 2.4.1.165

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

194747

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Cindy Wavelet-Vermuse (C)

Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France.

Sophie Groux-Degroote (S)

Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France.

Dorothée Vicogne (D)

Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France.

Virginie Cogez (V)

Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France.

Giulia Venturi (G)

Department of Experimental, Diagnostic and Specialty Medicine (DIMES), General Pathology Building, University of Bologna, 40126 Bologna, Italy.

Marco Trinchera (M)

Department of Medicine and Surgery, University of Insubria, 21100, Varese, Italy.

Guillaume Brysbaert (G)

Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France.

Marie-Ange Krzewinski-Recchi (MA)

Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France.

Elsa Hadj Bachir (E)

Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020 - U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.

Céline Schulz (C)

Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France.

Audrey Vincent (A)

Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020 - U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.

Isabelle Van Seuningen (I)

Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020 - U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.

Anne Harduin-Lepers (A)

Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France. Electronic address: anne.harduin-lepers@univ-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH